Publisher
Springer Science and Business Media LLC
Reference14 articles.
1. Juric D, Rodon J, Tabernero J, et al. Phosphatidylinositol 3-kinase alpha-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study. J Clin Oncol. 2018;36(13):1291–9.
2. Pereira B, Chin SF, Rueda OM, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016;7:11479.
3. Novartis. FDA approves Novartis Piqray®; the first and only treatment specifically for patients with a PIK3CA mutation in HR +/HER2− advanced breast cancer. 2019. [media release]. 28 May 2019.
4. Novartis. Novartis global pipeline. 2019.
https://www.novartis.com/our-science/novartis-global-pipeline
. Accessed 6 June 2019
5. Novartis. Piqray® (alpelisib) US prescribing information. 2019.
https://www.pharma.us.novartis.com
. Accessed 28 May 2019.
Cited by
191 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献